GlassScriptPhysician profile
Christopher M Renzi
NPI 1285179390
$17,807.92
in general payments reported to CMS, 2019-2025
65 companies · $4,116 in 2025
The $4,116 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,374 · 2022: $3,041 · 2023: $3,150 · 2024: $4,127 · 2025: $4,116.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,373.00 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,596.10 | 2021-2025 | |
| Novo Nordisk INC | $1,740.40 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,516.15 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,349.70 | 2021-2025 | Relistor, Xifaxan |
| Glaxosmithkline, LLC. | $1,098.50 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $697.58 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Astellas Pharma US INC | $548.66 | 2021-2025 | Veozah, Myrbetriq |
| Otsuka America Pharmaceutical, INC. | $525.39 | 2022-2025 | Rexulti |
| Lundbeck LLC | $501.16 | 2021-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $428.68 | 2021-2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $402.86 | 2021-2025 | Jardiance, Synjardy, Stiolto Respimat |
| Pfizer INC. | $401.63 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $366.50 | 2021-2025 | Trintellix, Gattex |
| Novartis Pharmaceuticals Corporation | $320.43 | 2021-2025 | |
| Collegium Pharmaceutical, INC. | $288.74 | 2022-2025 | Xtampza, Belbuca |
Show all 65 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $286.68 | 2021-2025 | Repatha, Otezla, Repatha |
| Shield Therapeutics INC | $275.28 | 2025 | |
| Aimmune Therapeutics, INC. | $268.47 | 2024-2025 | Zenpep, Vowst |
| Neurocrine Biosciences, INC. | $258.25 | 2023-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $256.73 | 2022-2025 | Caplyta |
| Daiichi Sankyo INC. | $234.18 | 2022-2025 | Injectafer |
| Indivior INC. | $220.86 | 2021-2025 | Sublocade |
| Merck Sharp & Dohme LLC | $220.55 | 2021-2025 | Verquvo, Belsomra, Capvaxive |
| Bayer Healthcare Pharmaceuticals INC. | $209.36 | 2021-2025 | |
| Xeris Pharmaceuticals, INC. | $205.68 | 2022-2024 | Gvoke Hypopen |
| Sumitomo Pharma America, INC. | $166.35 | 2024-2025 | Gemtesa |
| Alkermes, INC. | $165.94 | 2023-2025 | Lybalvi |
| Braeburn INC. | $162.29 | 2024-2025 | Brixadi |
| Kowa Pharmaceuticals America, INC. | $155.76 | 2022-2025 | Zoryve, Livalo, Seglentis |
| E.R. Squibb & Sons, L.L.C. | $146.31 | 2022-2025 | Eliquis, Camzyos |
| Horizon Therapeutics Plc | $144.23 | 2021-2022 | |
| Redhill Biopharma INC. | $121.50 | 2021-2022 | |
| Paratek Pharmaceuticals, INC. | $118.10 | 2021-2024 | Nuzyra |
| Orexo US, INC. | $111.39 | 2022-2023 | Zubsolv |
| Valinor Pharma, LLC | $107.53 | 2023-2025 | Movantik |
| Nestle Healthcare Nutrition INC. | $87.12 | 2021-2023 | |
| Almatica Pharma LLC | $82.50 | 2021-2023 | Loreev Xr |
| Tolmar, INC. | $72.93 | 2023-2024 | |
| Abbott Laboratories | $70.72 | 2022 | |
| Azurity Pharmaceuticals, INC. | $66.67 | 2025 | Alvesco, Azmiro |
| Biohaven Pharmaceutical Holding Company LTD. | $66.21 | 2022 | |
| Exact Sciences Corporation | $59.69 | 2023-2025 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $56.16 | 2021-2023 | |
| Sanofi-Aventis U.S. LLC | $53.71 | 2023-2025 | |
| Eisai INC. | $49.27 | 2021 | |
| Corium, LLC | $47.00 | 2023 | Azstarys |
| Biohaven Pharmaceuticals, INC. | $45.90 | 2021 | |
| Phathom Pharmaceuticals, INC. | $43.87 | 2024 | Voquezna |
| Genentech USA, INC. | $37.59 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $31.37 | 2021 | |
| Arbor Pharmaceuticals, INC. | $31.02 | 2021 | |
| Verona Pharma, INC. | $25.18 | 2025 | Ohtuvayre |
| Hologic Sales and Service, LLC | $24.14 | 2024 | Aptima |
| Ibsa Pharma INC. | $24.06 | 2025 | Tirosint, Flector, Licart |
| Evoke Pharma, INC. | $23.22 | 2022 | |
| Optinose US, INC. | $21.19 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $20.81 | 2023 | Ajovy |
| Inspire Medical Systems, INC. | $20.78 | 2025 | Inspire |
| Idorsia Pharmaceuticals US INC | $20.34 | 2022 | |
| Corcept Therapeutics | $19.72 | 2023 | Korlym |
| Ardelyx, INC. | $19.63 | 2023 | Ibsrela |
| Philips North America LLC | $19.50 | 2021 | |
| Vanda Pharmaceuticals INC. | $18.75 | 2025 | Fanapt |
| Cipher Pharmaceuticals US LLC | $16.73 | 2025 | Spinosad, Natroba |
| Axsome Therapeutics, INC. | $14.22 | 2025 | Auvelity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Renzi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.